We serve Chemical Name:4,7-Dioxo-7-thiophen-2-yl-heptanoic acid CAS:24090-18-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4,7-Dioxo-7-thiophen-2-yl-heptanoic acid
CAS.NO:24090-18-4
Synonyms:4,7-dioxo-7-thiophen-2-ylheptanoic acid
Molecular Formula:C11H12O4S
Molecular Weight:240.27600
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:476.4ºC at 760 mmHg
Density:N/A
Index of Refraction:
PSA:99.68000
Exact Mass:240.04600
LogP:2.14490
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4,7-dioxo-7-thiophen-2-ylheptanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,7-dioxo-7-thiophen-2-ylheptanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,7-dioxo-7-thiophen-2-ylheptanoic acid Use and application,4,7-dioxo-7-thiophen-2-ylheptanoic acid technical grade,usp/ep/jp grade.
Related News: The review considered two cases of AML in patients treated with an investigational medicine, bb1111, in a clinical trial for sickle cell disease. Although there have been no reports of AML with Zynteglo, both medicines use the same viral vector and there was a concern that the vector may be implicated in the development of the cancer (insertional oncogenesis). n-boc-indoline-7-carboxylic acid manufacturers For seniors most in need of care, high-quality health care often is beyond reach. ChenMed brings concierge-style medicine — and better health outcomes — to the neediest populations. Physician-led and privately owned, ChenMed is a provider of choice for some 20 Medicare Advantage health insurance plans. 4-(3,4-dichloroanilino)pyridine-3-sulfonamide suppliers Biogen hiked its revenue guidance for the year, saying it expects total sales of $10.65 billion to $10.85 billion this year. That’s up from its previous estimates of $10.45 billion to $10.75 billion. The new forecast assumes “modest” revenue from Aduhelm in 2021, ramping up thereafter, the company said. Gentamicin X2 vendor & factory.
